Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Dinaciclib (Primary) ; Pembrolizumab (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Acronyms KEYNOTE-155
- Sponsors Merck Sharp & Dohme
- 28 Nov 2017 Planned number of patients changed from 203 to 138.
- 15 Nov 2017 Planned number of patients changed from 138 to 203.
- 11 Apr 2016 Planned End Date changed from 1 Jan 2020 to 1 Feb 2020.